TY - JOUR
T1 - Frequency and outcomes of patients with increased mean pulmonary artery pressure at the time of liver transplantation
AU - DeMartino, Erin S.
AU - Cartin-Ceba, Rodrigo
AU - Findlay, James Y.
AU - Heimbach, Julie K.
AU - Krowka, Michael J.
PY - 2017/1
Y1 - 2017/1
N2 - Background. Pulmonary hypertension (PH) exists when mean pulmonary artery pressure (mPAP) is 25 mm Hg or greater. mPAP of 35 mm Hg or greater, with increased pulmonary vascular resistance from portopulmonary hypertension, has been associated with increased post-liver transplant (LT)mortality. However,mPAP of 35mmHg or greater can also occur in the setting of normal pulmonary vascular resistance from a high flow state and/or increased pulmonary venous volume.We describe the frequency of patients with mPAP of 35 mm Hg or greater at LTand correlate their clinical outcomes with hemodynamic characteristics. Methods. We reviewed hemodynamics of 300 consecutive adult patients undergoing LT. Primary and secondary outcomes were transplant hospitalization mortality and 1-year mortality. Results. Overall, PH was documented in 117 (39%) of 300 transplant recipients. Five patients were receiving ongoing treatment for portopulmonary hypertension at the time of transplant. mPAP of 35 mm Hg or greater was seen in 31 of 300 patients (10.3%; median, 38 mm Hg; range, 35-46 mm Hg). No intraoperative deaths occurred. Transplant hospitalization mortality was 0% for those with mPAP of 35 mm Hg or greater (vs 2.2% if mPAP < 35 mm Hg, P = 1.0). One-year mortality was similar for patients with and without mPAP of 35mmHg or greater (3.2% vs 6.0%, P = 1.0). No deaths were associated with right heart failure. Conclusions. At the time of LT, 39% of recipients had PH (mPAP ≥ 25 mm Hg) and 10.3% had mPAP ≥ 35 mm Hg. When associated with a high flow state and/or increased volume, transplant hospitalization and 1-year posttransplant outcomes were not adversely affected.
AB - Background. Pulmonary hypertension (PH) exists when mean pulmonary artery pressure (mPAP) is 25 mm Hg or greater. mPAP of 35 mm Hg or greater, with increased pulmonary vascular resistance from portopulmonary hypertension, has been associated with increased post-liver transplant (LT)mortality. However,mPAP of 35mmHg or greater can also occur in the setting of normal pulmonary vascular resistance from a high flow state and/or increased pulmonary venous volume.We describe the frequency of patients with mPAP of 35 mm Hg or greater at LTand correlate their clinical outcomes with hemodynamic characteristics. Methods. We reviewed hemodynamics of 300 consecutive adult patients undergoing LT. Primary and secondary outcomes were transplant hospitalization mortality and 1-year mortality. Results. Overall, PH was documented in 117 (39%) of 300 transplant recipients. Five patients were receiving ongoing treatment for portopulmonary hypertension at the time of transplant. mPAP of 35 mm Hg or greater was seen in 31 of 300 patients (10.3%; median, 38 mm Hg; range, 35-46 mm Hg). No intraoperative deaths occurred. Transplant hospitalization mortality was 0% for those with mPAP of 35 mm Hg or greater (vs 2.2% if mPAP < 35 mm Hg, P = 1.0). One-year mortality was similar for patients with and without mPAP of 35mmHg or greater (3.2% vs 6.0%, P = 1.0). No deaths were associated with right heart failure. Conclusions. At the time of LT, 39% of recipients had PH (mPAP ≥ 25 mm Hg) and 10.3% had mPAP ≥ 35 mm Hg. When associated with a high flow state and/or increased volume, transplant hospitalization and 1-year posttransplant outcomes were not adversely affected.
UR - http://www.scopus.com/inward/record.url?scp=85010211606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010211606&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000001517
DO - 10.1097/TP.0000000000001517
M3 - Article
C2 - 28009757
AN - SCOPUS:85010211606
SN - 0041-1337
VL - 101
SP - 101
EP - 106
JO - Transplantation
JF - Transplantation
IS - 1
ER -